Curis Lifesciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	61.05	48.67	18.75	4.92	-
Depreciation & Amortization	6.75	6.79	7.26	7.55	-
Loss (Gain) From Sale of Assets	-	-	-0.11	-0.05	-
Other Operating Activities	17.02	31.44	16.32	23.54	-
Change in Accounts Receivable	25.72	-5.5	-32.52	0.59	-
Change in Inventory	-94.38	-38.54	2.68	-24.39	-
Change in Accounts Payable	-9.48	-41.75	17.81	35.08	-
Change in Other Net Operating Assets	-24.31	1.69	3.37	2.21	-
Operating Cash Flow	-17.63	2.8	33.55	49.46	-
Operating Cash Flow Growth	-	-91.65%	-32.17%	-	-
Capital Expenditures	-0.93	-0.73	-6.23	-3.99	-
Sale of Property, Plant & Equipment	-	-	0.45	0.14	-
Other Investing Activities	0.7	0.12	0.23	0.12	-
Investing Cash Flow	-0.24	-0.62	-5.56	-3.73	-
Short-Term Debt Issued	-	19.7	12	1.81	-
Total Debt Issued	-	19.7	12	1.81	-
Short-Term Debt Repaid	-2.69	-	-	-	-
Long-Term Debt Repaid	-12.02	-10.74	-26.3	-31.43	-
Total Debt Repaid	-14.71	-10.74	-26.3	-31.43	-
Net Debt Issued (Repaid)	-14.71	8.96	-14.3	-29.63	-
Issuance of Common Stock	42.5	-	-	-	-
Other Financing Activities	-11.06	-8.49	-13.28	-16.16	-
Financing Cash Flow	16.72	0.47	-27.58	-45.79	-
Miscellaneous Cash Flow Adjustments	0	-	-	-	-
Net Cash Flow	-1.14	2.65	0.41	-0.05	-
Free Cash Flow	-18.56	2.07	27.31	45.47	-
Free Cash Flow Growth	-	-92.42%	-39.93%	-	-
Free Cash Flow Margin	-3.74%	0.58%	7.70%	19.15%	-
Free Cash Flow Per Share	-3.13	0.35	4.63	8.27	-
Cash Interest Paid	11.06	8.49	13.28	16.16	-
Cash Income Tax Paid	15.56	-	-	-	-
Levered Free Cash Flow	-39.11	-19.02	3.53	24.51	-
Unlevered Free Cash Flow	-32.2	-13.72	11.83	34.61	-
Change in Working Capital	-102.44	-84.1	-8.67	13.49	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.